Akero Therapeutics (NYSE: AKRO) — Perfil da empresa, notícias e dados financeiros
Akero Therapeutics is developing treatments for metabolic diseases, focusing on a novel therapy for non-alcoholic steatohepatitis.
Akero Therapeutics
Akero Therapeutics (NASDAQ:AKRO) is a biotechnology firm dedicated to developing innovative treatments for serious metabolic diseases, with a sharp focus on non-alcoholic steatohepatitis (NASH). At the heart of its operations is a drive to address the urgent needs of patients facing these life-threatening conditions, through the advancement of its lead product candidate, EFX, a novel therapy designed to ameliorate the effects of NASH. The company's projects span various stages of clinical development, aiming to demonstrate EFX's potential in improving liver health and providing a much-needed solution in the NASH treatment landscape. Akero Therapeutics' objectives are centered on pushing the boundaries of scientific discovery to improve patient care, driving forward clinical trials to bring their therapeutic solutions closer to market approval, and ultimately changing the treatment paradigm for metabolic diseases.
Resumo
Operações
Produtos e/ou serviços de Akero Therapeutics
- Efruxifermin (EFX) for NASH treatment: A FGF21 analogue undergoing clinical trials aimed at addressing the root causes of non-alcoholic steatohepatitis (NASH).
- EFX for serious metabolic disorders: Exploring EFX's potential in treating a range of metabolic diseases beyond NASH, capitalizing on its insulin-sensitizing and lipid-regulating effects.
- Combination therapies with EFX: Investigating EFX in combination with other therapies to enhance treatment outcomes for NASH and potentially other metabolic conditions.
- Pipeline expansion: Focusing on expanding the drug pipeline by exploring new molecular targets and pathways relevant to NASH and metabolic diseases.
- Disease diagnostics and patient identification: Developing diagnostic tools and algorithms to better identify candidates for NASH treatments, improving clinical trial enrollment and precision medicine approaches.
- Patient support and disease education: Offering comprehensive support and educational resources for patients diagnosed with NASH and metabolic disorders, emphasizing treatment adherence and lifestyle modification.
equipe executiva do Akero Therapeutics
- Dr. Andrew Cheng M.D., Ph.D.President, CEO & Director
- Dr. Jonathan M. Young J.D., Ph.D.Co-Founder, Executive VP, COO & Secretary
- Mr. William R. White J.D.Executive VP, CFO, Treasurer & Head of Corporate Development
- Mr. Scott A. GangloffChief Technical Officer
- Ms. Catriona YaleExecutive VP & Chief Development Officer
- Dr. Timothy Rolph Ph.D.Co-Founder & Chief Scientific Officer
- Mr. Thomas RossSenior VP & Head of Legal
- Mr. John J. SchembriSenior VP & Head of Finance
- Mr. Patrick LamySenior Vice President of Commercial Strategy
Principais indicadores financeiros
Resultados divulgados pela Akero Therapeutics, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -285,4 mi | -252,1 mi | |
| 0 | -172,9 mi | -151,8 mi | |
| 0 | -115,2 mi | -112 mi | |
| 0 | -100,9 mi | -100,7 mi |